In The News Posted December 9, 2019 Share Posted December 9, 2019 LOS ANGELES, Dec. 9, 2019 /PRNewswire/ -- ImaginAb Inc., a clinical-stage immuno-oncology imaging company, announces it has initiated its Phase II clinical trial of its lead product, CD8 tracer 89Zr-Df-IAB22M2C, at Penn Medicine in Philadelphia, PA. Penn Medicine is one of the world's... View the full article Link to comment Share on other sites More sharing options...
Recommended Posts
Archived
This topic is now archived and is closed to further replies.